Profile data is unavailable for this security.
About the company
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
- Revenue in USD (TTM)555.06m
- Net income in USD-39.48m
- Incorporated2015
- Employees1.03k
- LocationBioventus Inc4721 EMPEROR BOULEVARD, SUITE 100DURHAM 27703United StatesUSA
- Phone+1 (919) 474-6700
- Fax+1 (302) 655-5049
- Websitehttps://www.bioventus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Butterfly Network Inc | 76.22m | -98.51m | 690.32m | 225.00 | -- | 3.80 | -- | 9.06 | -0.4708 | -0.4708 | 0.3627 | 0.8537 | 0.2543 | 0.6416 | 4.45 | 338,755.60 | -32.87 | -- | -38.53 | -- | 29.60 | -- | -129.25 | -- | 2.95 | -- | 0.00 | -- | -10.21 | -- | 20.76 | -- | -- | -- |
| Orthofix Medical Inc | 784.25m | -119.03m | 722.63m | 1.63k | -- | 1.37 | -- | 0.9214 | -3.14 | -3.14 | 20.72 | 13.76 | 0.8844 | 1.17 | 6.56 | 479,956.60 | -13.42 | -8.88 | -16.31 | -10.96 | 68.05 | 72.37 | -15.18 | -9.28 | 1.11 | -3.12 | 0.2069 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Embecta Corp | 1.12bn | 69.70m | 797.44m | 2.20k | 11.45 | -- | 7.36 | 0.7127 | 1.21 | 1.21 | 19.36 | -13.24 | 0.8882 | 2.11 | 11.60 | 508,590.90 | 5.53 | -- | 7.91 | -- | 66.42 | -- | 6.23 | -- | 1.61 | 2.06 | 1.88 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| Figs Inc | 548.65m | 10.84m | 800.40m | 354.00 | 79.99 | 1.98 | 48.33 | 1.46 | 0.059 | 0.059 | 3.08 | 2.38 | 1.11 | 1.33 | 65.26 | 1,549,845.00 | 2.20 | -- | 2.64 | -- | 67.67 | -- | 1.97 | -- | 3.28 | -- | 0.00 | -- | 7.87 | -- | 6.85 | -- | -- | -- |
| Castle Biosciences Inc | 311.88m | 6.08m | 834.90m | 610.00 | 149.11 | 1.89 | 42.75 | 2.68 | 0.1999 | 0.1999 | 11.07 | 15.77 | 0.6562 | 9.15 | 7.15 | 511,275.40 | 1.28 | -9.43 | 1.40 | -10.17 | 81.90 | 80.58 | 1.95 | -28.46 | 7.64 | -- | 0.0228 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Paragon 28 Inc | 245.00m | -63.08m | 838.38m | 430.00 | -- | 6.02 | -- | 3.42 | -0.7599 | -0.7599 | 2.95 | 1.67 | 0.823 | 0.6362 | 7.06 | 569,755.80 | -21.19 | -- | -25.76 | -- | 75.22 | -- | -25.75 | -- | 1.60 | -4.20 | 0.4424 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Cytek Biosciences Inc | 201.21m | -10.16m | 843.71m | 645.00 | -- | 2.21 | -- | 4.19 | -0.0782 | -0.0782 | 1.52 | 2.97 | 0.3982 | 1.60 | 3.72 | 297,647.90 | -2.01 | -- | -2.29 | -- | 54.92 | -- | -5.05 | -- | 5.47 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Avanos Medical Inc | 681.50m | 21.70m | 854.80m | 3.77k | 39.75 | 0.6951 | 12.64 | 1.25 | 0.4679 | 0.3385 | 14.70 | 26.76 | 0.4031 | 1.90 | 5.16 | 180,721.30 | 1.28 | -0.6527 | 1.45 | -0.7338 | 55.51 | 54.45 | 3.18 | -1.60 | 1.46 | 9.84 | 0.1164 | -- | -1.58 | 0.6357 | -146.05 | -- | -18.37 | -- |
| CeriBell Inc | -100.00bn | -100.00bn | 936.89m | -- | -- | -- | -- | -- | -- | -- | -- | 0.336 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.14 | -- | 0.6304 | -- | 74.47 | -- | 20.72 | -- | -- | -- |
| Bioventus Inc | 555.06m | -39.48m | 950.32m | 1.03k | -- | 6.39 | -- | 1.71 | -0.6172 | -0.6172 | 8.68 | 1.83 | 0.7023 | 1.95 | 4.73 | 572,227.80 | -6.47 | -5.52 | -9.13 | -7.27 | 67.00 | 68.25 | -9.22 | -10.94 | 0.9866 | 1.13 | 0.6725 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Owens & Minor, Inc. | 10.66bn | -48.79m | 952.30m | 13.70k | -- | 1.09 | 4.30 | 0.0893 | -0.6346 | -0.6346 | 139.27 | 11.35 | 2.09 | 7.26 | 15.86 | 778,172.30 | -0.9561 | 1.32 | -1.49 | 2.07 | 20.72 | 16.48 | -0.4576 | 0.5614 | 0.4519 | 2.03 | 0.6831 | 0.798 | 3.80 | 1.87 | -284.47 | -- | 25.91 | -- |
| Pulse Biosciences Inc | 0.00 | -46.13m | 1.09bn | 56.00 | -- | 13.74 | -- | -- | -0.8069 | -0.8069 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -58.03 | -93.21 | -62.84 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Artivion Inc | 384.90m | -846.00k | 1.19bn | 1.50k | -- | 3.89 | 51.81 | 3.08 | -0.0235 | -0.0235 | 9.25 | 7.27 | 0.4879 | 1.68 | 5.50 | 256,599.30 | -0.1079 | -2.20 | -0.1242 | -2.36 | 64.53 | 65.51 | -0.2211 | -5.34 | 1.33 | 1.10 | 0.51 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
| BioLife Solutions Inc | 118.41m | -26.44m | 1.20bn | 409.00 | -- | 3.69 | -- | 10.13 | -0.5826 | -1.01 | 2.59 | 7.04 | 0.2987 | 1.69 | 5.58 | 289,513.40 | -6.67 | -13.76 | -7.37 | -15.04 | 46.15 | 36.76 | -22.33 | -42.99 | 1.78 | -4.03 | 0.0614 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
| Establishment Labs Holdings Inc | 153.07m | -70.61m | 1.21bn | 933.00 | -- | 36.83 | -- | 7.88 | -2.58 | -2.58 | 5.57 | 1.17 | 0.5534 | 0.7916 | 2.51 | 168,580.40 | -25.53 | -33.22 | -31.21 | -41.12 | 65.08 | 64.73 | -46.13 | -43.19 | 2.29 | -4.51 | 0.856 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
Data as of Nov 22 2024. Currency figures normalised to Bioventus Inc's reporting currency: US Dollar USD
31.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Juniper Investment Co. LLCas of 30 Sep 2024 | 6.94m | 10.66% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 4.35m | 6.69% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.46m | 3.77% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.03m | 3.12% |
| Geode Capital Management LLCas of 30 Sep 2024 | 940.50k | 1.45% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 837.51k | 1.29% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 736.41k | 1.13% |
| Royce & Associates LPas of 30 Sep 2024 | 697.70k | 1.07% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 676.50k | 1.04% |
| American Century Investment Management, Inc.as of 30 Sep 2024 | 638.03k | 0.98% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
